Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Oct 27: Coherus BioSciences and Shanghai Junshi Biosciences won approval Friday for Loqtorzi (toripalimab-tpzi)in combination with cisplatin and gemcitabinefor the first-line treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC)
Editor's note: This popular story from the Daily Briefing's archives was republished on June 26, 2026
North America's dominance is attributed to the rapid expansion of wellness and IV infusion clinics, high healthcare expenditure, growing consumer interest in preventive healthcare, and increasing adoption of anti-aging and antioxidant therapies
Abstract Aims/hypothesis Glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) are secreted from enteroendocrine L cells in response to nutrient ingestion
A recent review has highlighted a number of dermatological effects, rare but significant, including hypersensitivity reactions, fat inflammation (panniculitis), bullous pemphigoid, and measles-like (morbilliform) drug eruptions [3] that may occur with their use
US$ 24.78
US$ 20.71
US$ 24.81
